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REVIEW
Abstract: The management of acute episodes in schizophrenia is frequently initiated in the
psychiatric emergency department and requires rapid intervention to relieve distress and
psychiatric symptoms. Both non-pharmacological and pharmacological interventions are
needed to calm the patient and prevent potential harm to the patient or others. Treatment is a
step-by-step process including management of behavioral symptomatology, diagnosis of
potential organic causes, and evaluation of potential substance abuse. Better care is delivered
if predefined standard operating procedures are adopted systematically. The ultimate goal of
treatment is to establish a therapeutic alliance with the patient. Atypical antipsychotics given
orally are recommended as a first-line treatment. As the treatment endpoint is calmness rather
than sleep, a non-sedative antipsychotic agent is usually preferred. Drug tolerance is a major
issue for the patient. Amisulpride is an effective atypical antipsychotic agent in this context.
The optimal dose is 800 mg/day, which is effective on positive and negative symptoms and
can be given from the first day with a low risk of extrapyramidal symptoms. Since drug–drug
interactions are limited, agitation and anxiety may be controlled by short-term adjunctive
therapy with benzodiazepines. In conclusion, amisulpride is an appropriate first-line treatment
for the management of acute psychosis.
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Management of acute psychosis
The management of acute psychosis in schizophrenia is frequently initiated in the
psychiatric emergency department. At this stage, patients are often distressed, not
necessarily cooperative, out-of-touch, and agitated. Rapid and appropriate treatment
is necessary to relieve distress and psychiatric symptoms, to calm the patient, to
maintain the patient in a secure treatment environment, and prevent potential harm
to the patient or others (Battaglia 2005). Although treatment habits may differ from
one hospital to another, expert consensus has been proposed in order to set “best
practice” recommendations for acute psychiatric emergences (Allen et al 2001). Acute
psychosis is often associated with emergency because of intensity of patient suffering,
risk of suicide, and potential harm towards others (Steinert et al 1999). Substance
abuse is a frequent comorbid condition. Satisfaction of patients and their families
with staff management and medication tolerance is particularly important at this
stage of the disease.
Pharmacological management of psychotic
symptoms
Antipsychotic medication is recommended for the treatment of psychotic symptoms
during this acute phase. There has been much debate about the relative advantages
and disadvantages of oral versus intramuscular route of administration. Although
intramuscular formulations have the advantage of ensuring rapid and effective drug
delivery, oral medication is generally preferred in the emergency setting if clinically
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feasible; intramuscular administration being usually
prescribed only for uncooperative patients (Allen et al 2001).
Certain intramuscular formulations are poorly-tolerated,
which may compromise long-term adherence to therapy
(Currier and Medori 2006).
The attending physician can select from a wide choice
of oral antipsychotic medications. Factors influencing the
choice of drug include tolerability, rate of onset of efficacy,
spectrum of efficacy, and dosage regimen. Side effects,
particularly extrapyramidal symptoms, are an important
determinant of short- and long-term adherence (Perkins
2002). In this respect, the introduction of atypical
antipsychotic drugs which are characterized by a lower
propensity for extrapyramidal effects, represent an important
advance. A rapid onset of antipsychotic effect is important
to control symptoms and to optimize patient retention on
treatment. Antipsychotic drugs that can be given
immediately at the optimal dose may have advantages in
this respect over drugs that need titration. The choice of the
right dose to obtain an effective treatment response is critical.
Antipsychotic drugs also differ in their secondary
psychotropic effects, some being rather sedative and others
having a more activating effect. This heterogeneity of
therapeutic dimensional profiles is likely to be due to the
relative pharmacological specificity of antipsychotic drugs
for different monoamine receptor subtypes (Reynolds 1994;
Tamminga 2003). In patients who are highly agitated, a
sedative neuroleptic may be considered, although, as
described below, use of a non-sedative antipsychotic with
an adjunctive benzodiazepine provides a more flexible
therapeutic strategy. In contrast, in patients who are
unresponsive or uncooperative due to negative symptoms,
an antipsychotic with proven efficacy on negative symptoms
may be more appropriate. In patients who are uncooperative,
drugs requiring a single daily intake may be preferable to
those requiring multiple daily administration. Finally, drugs
that have important pharmacokinetic or pharmacodynamic
interactions with other drugs that may be potentially
prescribed in acute psychosis should be used with caution.
It is also important to consider the transition to
maintenance therapy. Wherever possible, the antipsychotic
used successfully to control symptoms in the acute phase
should be continued into the maintenance phase, and
switching treatments avoided. It is thus important to take
into account the long-term tolerability of antipsychotic
medication when choosing a drug to use in the initial phase.
For the same reason, combinations of antipsychotic drugs
should also be avoided in the acute phase in favor of
monotherapy at an adequate dose to achieve successful
symptom control.
Pharmacological management of
agitation
For rapid control of agitation, physicians may choose to
use a sedative antipsychotic drug from the outset to manage
both psychosis and agitation simultaneously. The
disadvantage of such a strategy is that the sedative effect
can not be removed during the maintenance phase of therapy
when it no longer has a therapeutic role to play and remains
as a side-effect detrimental to the patient’s performance and
well-being. Dose reduction to attenuate sedation may be
associated with loss of control over psychotic symptoms.
A more flexible alternative is to combine a non-sedative
antipsychotic with an anxiolytic drug to control the two
symptom clusters independently. In this way, the anxiolytic
drug treatment can be stopped when the patient is no longer
agitated without compromising control of psychosis.
Benzodiazepines are the treatment of choice for the short-
term management of agitation and anxiety in patients with
schizophrenia (Wolkowitz and Pickar 1991). A long-acting
drug such as diazepam, lorazepam, or alprazolam should
be chosen to ensure sustained symptom control (Barbee et
al 1992). In particular, well-designed recent studies have
demonstrated the utility of lorazepam in association with
an antipsychotic in the initial control of agitation in acute
psychotic episodes of schizophrenia (eg, Battaglia et al 1997;
Foster et al 1997). Intramuscular administration of
lorazepam may be useful in the emergency room when
patients are highly agitated and uncooperative. Long-term
use of benzodiazepines should be avoided to prevent the
development of benzodiazepine dependence and emergence
of rebound anxiety when treatment is discontinued. An
antidepressant with anxiolytic activity may be considered
if longer-term treatment of anxiety is needed.
Amisulpride
The development of atypical antipsychotic drugs represents
a significant advance in the treatment of schizophrenia.
Some of these drugs may have a more pronounced
antipsychotic effect than previously available drugs (Leucht
et al 1999; Chakos et al 2001; Davis et al 2003) and all are
associated with a lower incidence of extrapyramidal side-
effects for an equivalent level of symptom control compared
with conventional drugs (Leucht et al 1999; Geddes et al
2000; Davis et al 2003). Since the occurrence of such side-Therapeutics and Clinical Risk Management 2007:3(1) 5
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effects is a major determinant of compliance to antipsychotic
treatment, the use of the newer atypical drugs allows less
treatment discontinuation (Kemmler et al 2005) and thus
more consistent long-term control. For this reason, atypical
antipsychotics are now recommended as the first-line
treatment of choice for patients with schizophrenia in many
countries (eg, NICE 2002).
Amisulpride is a D2/D3 dopamine receptor antagonist
with well-characterized atypical antipsychotic properties
(McKeage and Plosker 2004). The efficacy of amisulpride
in the control of acute psychosis has been demonstrated in
twelve randomized clinical trials (Leucht et al 1999, 2002;
Geddes et al 2000; Mota et al 2002; Davis et al 2003). These
trials have generally demonstrated superior efficacy to that
of conventional antipsychotics (Möller et al 1997; Wetzel
et al 1998; Puech et al 1998; Carrière et al 2000; Colonna et
al 2000) and similar efficacy to two other atypical drugs,
risperidone (Peuskens et al 2002; Sechter et al 2002) and
olanzapine (Mortimer et al 2004). The clinical effects
observed in these different trials are illustrated in Figure 1.
The overall clinical response corresponded to an 11% (95%
confidence limits: 6%–16%) improvement over
conventional antipsychotics. Although outside the scope of
this review, several clinical trials of six or twelve month
duration have demonstrated that the drug is safe and effective
for maintenance treatment of psychosis (Naber et al 2003)
and for treatment of chronic schizophrenia syndromes
(Storosum et al 2002).
Meta-analysis also indicates the relative benefit of
atypical antipsychotic drugs over conventional
antipsychotics (Davis et al 2003). Amisulpride demonstrates
a similar clinical effect to risperidone and olanzapine, a
smaller effect relative to clozapine but an apparently
improved response to that observed by a number of other
drugs (Figure 2). However, these comparisons must be
interpreted with caution due to methodological differences
between the individual studies.
Amisulpride demonstrated more acceptable and more
favorable tolerability, in the treatment of acute psychosis,
compared with conventional antipsychotic drugs. The
adverse events reported in eleven randomized clinical trials
have been pooled in a global analysis (Coulouvrat and
Dondey-Nouvel 1999). The most frequent adverse events
encountered are listed in Table 1. The incidence of
extrapyramidal effects, in general, and of dyskinesia and
hypertonia, in particular, was significantly lower in patients
treated with amisulpride compared with those receiving
conventional antipsychotic drugs.
Indeed, extrapyramidal effects, endocrine effects and
weight gain are of particular relevance for the tolerability
of antipsychotic drugs. Meta-analysis of the clinical trials
comparing amisulpride with conventional antipsychotics
Figure 1 Meta-analysis of effect sizes in clinical studies of amisulpride compared with first-generation drugs with respect to primary efficacy outcome (change in
score on the Brief Psychiatric Rating Scale). 95% confidence intervals were generated using a randomized effects model. Reprinted with permission from the American
Journal of Psychiatry, Copyright © 2002, American Psychiatric Association. Leucht S, Pitschel-Walz G, Engel RR, et al. 2002. Amisulpride, an unusual “atypical”
antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry, 159:180-90.
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demonstrates that use of antiparkinsonian medication was
25% lower (95% confidence intervals: 17%–32%) in
patients receiving amisulpride (Leucht et al 2002) (Figure
3) in direct comparison to risperidone or olanzapine
(Peuskens et al 1999; Sechter et al 2002; Mortimer et al
2004). The extent of extrapyramidal symptoms and recourse
to anticholinergic medication were very similar in head to
head trials with these compounds.
With regard to endocrine effects, amisulpride use is
associated with elevated serum prolactin in many patients
(Coulouvrat and Dondey-Nouvel 1999). Impotence and
delayed ejaculation were reported less frequently in
amisulpride-treated patients than in those treated with
risperidone. Amenorrhoea was encountered only in the
amisulpride group (6.2% ) when compared with olanzapine
(Mortimer et al 2004). Weight gain is less frequent and lower
in patients receiving amisulpride than in patients treated with
risperidone (Sechter et al 2002) or olanzapine (Mortimer et
al 2004).
Table 1 Most frequently-observed treatment-emergent adverse events in clinical trials of amisulpride in the treatment of acute
psychosis. Only those events observed in more than 3% of subjects in any treatment group are listed. The frequency of events
indicated in bold was significantly different (p<0.05) in the risperidone or haloperidol group compared with the amisulpride group.
Adapted from Coulouvrat and Dondey-Nouvel (1999).
Adverse event Amisulpride Haloperidol Risperidone
(n=579) (n=214) (n=113)
Extrapyramidal disorder 15% 31% 12%
Insomnia 11% 12% 7%
Hyperkinesia 9% 10% 10%
Anxiety 9% 11% 6%
Weight gain 7% 2% 5%
Agitation 6% 6% 4%
Headache 4% 3% 10%
Psychosis 4% 2% 1%
Constipation 4% 3% 1%
Amenorrhoea (F only) 4% - -%
Non-puerperal galactorrhoea (F only) 4% 1% 4%
Somnolence 3% 5% 4%
Dyskinesia 3% 7% -
Hypertonia 2% 6% 5%
Vomiting 2% 2% 4%
Rhinitis 2% 1% 8%
Fatigue 2% 1% 4%
Impotence (M only) 1% 2% 5%
Abbreviations: M, male; F, female.
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Ziegler (1989)
Saletu et al (1994)
Figure 3 Meta-analysis of effect sizes in clinical studies of amisulpride compared
with first-generation drugs with respect to recourse to anticholinergic
medication. 95% confidence intervals were generated using a randomized effects
model. Reproduced with permission from the American Journal of Psychiatry,
Copyright © 2002, American Psychiatric Association. Leucht S, Pitschel-Walz G,
Engel RR, et al. 2002. Amisulpride, an unusual “atypical” antipsychotic: a meta-
analysis of randomized controlled trials. Am J Psychiatry, 159:180-90.
Figure 2 Meta-analysis of effect sizes of second-generation antipsychotic drugs
compared to first-generation drugs with respect to primary efficacy outcome.
Data for amisulpride are combined from twelve individual studies. Copyright ©
2005. Reprinted with permission from Davis JM, Chen N. 2005. Old versus new:
weighing the evidence between the first- and second-generation antipsychotics.
Eur Psychiatry, 20:7-14.
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Choosing the right dose
The most appropriate dose of amisulpride for the treatment
of acute psychosis has been derived from dose-ranging
studies, single floating dose studies, and neuroimaging
studies. These have consistently supported 800 mg/day as
the optimal dose.
Dose-ranging studies
A single dose-ranging study has been reported for
amisulpride in acute psychosis (Puech et al 1998). This
evaluated four doses of amisulpride (100 mg/day, 400 mg/
day, 800 mg/day, and 1200 mg/day) and haloperidol 16 mg/
day in five parallel groups of 61–65 patients treated for four
weeks. The reference treatment group was the 100 mg/day
group, this dose being considered to be sub-therapeutic
(pseudo-placebo). Efficacy was assessed as the change from
baseline on the Brief Psychiatric Rating Scale (BPRS)
(Overall and Gorham 1962). A dose response-curve was
obtained (Figure 4) with the largest difference in score from
baseline being observed in the 800 mg/day treatment group.
The 800 mg/day dose was the only one where there was a
significantly larger difference in score (p<0.05) compared
with the 100 mg/day treatment group. A subsequent post
hoc analysis of the data from this study revealed that, with
the exception of the anergia dimension, responses were
highest in all dimensions of the BPRS at the 800 mg dose.
The authors concluded that target doses of 700–800 mg
seemed to be the most appropriate for the treatment of acute
psychosis (Müller et al 2002).
The proportion of patients in whom adverse events were
reported was similar in all treatment groups. Extrapyramidal
effects were assessed with the Simpson-Angus Scale
(Simpson and Angus 1970). The maximal change in score
from baseline was dose-related, although only the changes
observed in the amisulpride 1200 mg/day and haloperidol
groups were significantly higher from that in the reference
(amisulpride 100 mg/day) group (Figure 5). At study end,
changes from baseline in Simpson-Angus Scale scores were
rather small, except in the haloperidol treatment group. The
results of this study indicate that the dose of 800 mg/day
provides the best risk-benefit ratio for the majority of
patients in the treatment of acute psychosis.
Single floating dose studies
Information on the optimal dose of amisulpride can also be
found from single floating dose studies. In such studies, the
initial dose of amisulpride is fixed and then tailored in
individual patients depending upon clinical response. The
final dose used corresponds to that considered the most
appropriate from the point of view of clinical judgment. In
the single study where the starting dose of amisulpride was
above 800 mg/day (Wetzel et al 1998), the dose was reduced
in 50% of patients. In all the studies where a starting dose
below 800 mg/day was used, the dose was increased over
the course of the study. These findings suggest that
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Figure 5 Extrapyramidal impact of amisulpride as a function of dose. The data
represent the mean changes from baseline on the Simpson-Angus Scale (SAS)
after initiation of treatment with the indicated doses of amisulpride or
haloperidol.  The open columns represent the maximal change from baseline
observed over the course of the study and the filled columns the residual
change at study end. Data are taken from Puesch et al 1998.
Figure 4 Antipsychotic effect of amisulpride as a function of dose. The data
represent the mean (SD) scores on the Brief Psychiatric Rating Scale (BPRS) at
inclusion (filled symbols) and after treatment (open symbols) for four weeks
with the indicated doses of amisulpride or haloperidol. Data are taken from
Puech et al 1998.Therapeutics and Clinical Risk Management 2007:3(1) 8
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physicians adjusted the dose to converge in the range of
600–800 mg/day. In one study (Möller et al 1997), the dose
was initiated at 800 mg/day: here, the dose was adjusted in
only 17% of patients, always in a downward direction.
Neuroimaging studies
The introduction of high-resolution positron emission
tomography (PET) in the 1980s allowed the molecular target
of antipsychotic drugs in the brain, the D2 dopamine receptor
to be visualized and quantified. A series of studies performed
in Sweden led Farde and colleagues (1992) to postulate that
a robust antipsychotic response to most antipsychotics (the
notable exception being clozapine) was associated with a
70%–80% occupancy of striatal D2 receptors. Lower levels
of receptor occupancy were associated with sub-optimal
antipsychotic effects and higher levels of occupancy with
the manifestation of prominent extrapyramidal effects.
The occupation of striatal D2 dopamine receptors by
amisulpride in patients with schizophrenia has since been
evaluated using [
71Br]-bromolisuride PET (Martinot et al
1996). The study demonstrated a curvilinear relationship
between amisulpride dose and receptor occupancy, with the
critical 70%–80% degree of occupancy being obtained over
the 630–910 mg dose range (Figure 6). These results also
argue in favor of the choice of the 800 mg/day dose as the
most appropriate for optimal antipsychotic action.
Dose adjustment
Neither dose titration nor the use of a loading dose is required
for amisulpride and the 800 mg/day dose can be used
immediately from the first day. This is due to the relatively
simple pharmacokinetics of amisulpride, with rapid
absorption and minimal redistribution. This allows steady-
state plasma concentrations following repeated dosing to
be obtained within 48 h and 72 h (Rosenzweig et al 2002).
The ability to use amisulpride at the optimal dose from
the first day permits rapid control of psychotic symptoms
(Figure 7). This might be an advantage for amisulpride
compared with other antipsychotic drugs for which dose
titration is needed.
Monitoring and precautions for use
Although no particular monitoring procedures are required
when using amisulpride for the treatment of acute psychosis
in most patients, the use of the drug has been associated
with prolongation of the QT interval and should thus be
used with care in patients with cardiac rhythm disorders.
These patients should be monitored regularly by
electrocardiogram. Amisulpride is contra-indicated in
patients taking drugs affecting cardiac rhythm. Unlike many
antipsychotic drugs, amisulpride is not extensively
metabolized by hepatic enzymes (Rosenzweig et al 2002)
and thus can be used at the standard doses in patients with
hepatic impairment. Amisulpride is eliminated in the urine
and in patients with impaired renal function, the dose should
be reduced in line with creatinine clearance. A pilot study
(Riedel et al 2005) provided preliminary evidence that
amisulpride 400 mg/day is efficacious for the control of acute
psychosis in the elderly.
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Figure 7 Evolution of Brief Psychiatric Rating Scale (BPRS) total scores after
administration of amisulpride 800 mg in patients with acute psychosis. Data are
taken from Möller et al 1997.Therapeutics and Clinical Risk Management 2007:3(1) 9
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Managing agitation
Although amisulpride is effective in controlling psychotic
symptoms, it is not sedative and complementary strategies
need to be instituted at the beginning of treatment to control
agitation and anxiety if these occur to a significant extent.
The most appropriate strategy is use of a benzodiazepine.
The benzodiazepine can subsequently be stopped when
agitation is adequately controlled so that the patient is not
unnecessarily sedated in the long-term. Amisulpride is well
suited to such a strategy as it has only a limited capacity for
drug interactions due to weak protein binding and lack of
interactions with cytochrome P450 drug-metabolizing
enzymes (Canal et al 2004). It can thus be used safely in
combination with benzodiazepines and other anxiolytics.
In particular, a pharmacodynamic interaction study (Perault
et al 1998) of amisulpride and lorazepam revealed no
interaction between the two drugs. Adjunctive lorazepam
use was permitted in the randomized clinical trials of
amisulpride in the treatment of acute psychosis and the
observed improvements in the ‘activation’ dimension of the
BPRS, which measures agitation and includes tension,
hostility, uncooperativeness, and excitement, were
comparable with those measured in the other dimensions.
Moreover, short-term control of agitation as measured in
this way was comparable with that obtained with the sedative
atypical, olanzapine (Figure 8). The use of concomitant
psychotropic drugs in this study was similar between the
amisulpride and olanzapine treatment groups.
Benzodiazepines were administered to 47.9% of
amisulpride-treated patients and 50.8% of olanzapine-
treated patients. Use of antidepressants was reported in <5%
of patients in each group.
In situations where there is no immediate danger, non-
pharmacological interventions such as verbal de-escalation
may be used to manage the patient’s agitation. Every person
from the emergency staff, from the reception nurse to
medical staff, is involved in this process. Verbal and non-
verbal techniques are useful in communicating with the
patient. They comprise a calm, warm tone of voice, clear
explanation of the treatment process, family reassurance as
well as appropriate body position and eye-contact.
In some situations of extreme agitation, where there is a
risk of aggression to others, or in cases of disease denial,
the use of mechanical restraints such as body belts may be
required. This solution should be carefully examined in
respect of the patient’s civil liberties and staff must be trained
to minimize trauma to the patient.
Conclusion
The management of acute psychosis is based on analysis of
symptoms at presentation and requires step by step
adjustment. The primary goal is reduction of patient distress.
It is often associated with management of agitation and
sometimes aggressive behavior. Antipsychotic medication
such as amisulpride is an appropriate first-line treatment as
it is both effective and well tolerated. The optimal dose of
800 mg/day can be given from the first day, since there is
no need for dose titration. In case of agitation and anxiety,
short-term adjunctive benzodiazepine therapy is necessary.
The use of physical restraint must be a last-resort
management option. The ultimate goal of the treatment is
to establish a therapeutic alliance with the patient. The
transition between the acute and maintenance phases of
treatment can be conveniently accomplished, although the
800 mg daily dose, optimal for the treatment of the acute
phase, may be reduced afterwards to achieve the lowest
adequate maintenance dose.
Figure 8 Evolution of Brief Psychiatric Rating Scale (BPRS) dimension scores in
a comparative randomised clinical trial of amisulpride versus olanzapine in the
treatment of acute psychosis. Data are presented as mean (± SD) change from
baseline at two months in patients with acute schizophrenia treated with
amisulpride (filled columns) or olanzapine (open columns). Adapted from Martin
et al 2002.
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Table 2 Dose evaluation in randomised clinical trials of
amisulpride in the acute treatment of schizophrenia using a
single floating dose.
Study Starting dose Final dose
(mg/day) (mg/day)
Wetzel et al 1998 1000 907±177
Möller et al 1997 800 Maintained in 83%
Carrière et al 2000 800 600–800
Sechter et al 2002 400 683±204
Hwang et al 2003 400 630±154
Mortimer et al 2004 400 504±150Therapeutics and Clinical Risk Management 2007:3(1) 10
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